GLAXOSMITHKLINE
GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach ... focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.
GLAXOSMITHKLINE
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1929-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.gsk.com
Total Employee:
10001+
Status:
Active
Contact:
2157517173
Email Addresses:
[email protected]
Total Funding:
25.51 M USD
Technology used in webpage:
Google Font API LetsEncrypt Font Awesome Domain Not Resolving Mobile Non Scaleable Content Nginx Euro Organization Schema IPv6 JsDelivr
Similar Organizations
Bayer
Bayer is a life science company that specializes in the areas of health care and agriculture.
GSK - Cephalosporins Antibiotics Business
GlaxoSmithKline's Cephalosporins based brands composed of Zinnat, Zinacef and Fortum
Jaber Ibn Hayyan Pharmaceutical
Jaber Ibn Hayyan Pharmaceutical manufactures drugs like anti-biotic, non-antibiotic , topical, oral and others.
Selvita
Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-05-31 | Affinivax | Affinivax acquired by GlaxoSmithKline | 2.1 B USD |
| 2022-04-13 | Sierra Oncology | Sierra Oncology acquired by GlaxoSmithKline | 1.9 B USD |
| 2019-09-12 | Sitari Pharmaceuticals | Sitari Pharmaceuticals acquired by GlaxoSmithKline | N/A |
| 2018-12-03 | TESARO | TESARO acquired by GlaxoSmithKline | 5.1 B USD |
| 2015-02-11 | GlycoVaxyn | GlycoVaxyn acquired by GlaxoSmithKline | 190 M USD |
| 2013-05-29 | Okairos | Okairos acquired by GlaxoSmithKline | 325 M USD |
| 2012-08-03 | Human Genome Sciences | Human Genome Sciences acquired by GlaxoSmithKline | 3 B USD |
| 2012-05-15 | CellZome | CellZome acquired by GlaxoSmithKline | 61 M GBP |
| 2010-12-13 | MaxiNutrition | MaxiNutrition acquired by GlaxoSmithKline | 162 M GBP |
| 2010-12-07 | Nanjing MeiRui Pharma Co., Ltd. | Nanjing MeiRui Pharma Co., Ltd. acquired by GlaxoSmithKline | 70 M USD |
Investors List
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-23 | LifeMine Therapeutics | GlaxoSmithKline investment in Series C - LifeMine Therapeutics | 175 M USD |
| 2020-12-18 | Adrestia Therapeutics | GlaxoSmithKline investment in Series A - Adrestia Therapeutics | 172 M GBP |
| 2020-07-20 | CureVac | GlaxoSmithKline investment in Corporate Round - CureVac | 130 M GBP |
| 2020-04-07 | Vir Biotechnology | GlaxoSmithKline investment in Post-IPO Equity - Vir Biotechnology | 250 M USD |
| 2019-09-18 | SetPoint Medical | GlaxoSmithKline investment in Venture Round - SetPoint Medical | 15.7 M USD |
| 2019-04-01 | SpringWorks Therapeutics | GlaxoSmithKline investment in Series B - SpringWorks Therapeutics | 125 M USD |
| 2018-07-24 | 23andMe | GlaxoSmithKline investment in Corporate Round - 23andMe | 300 M USD |
| 2016-02-02 | Spero Therapeutics | GlaxoSmithKline investment in Series B - Spero Therapeutics | 30 M USD |
| 2015-11-04 | Atreca | GlaxoSmithKline investment in Series A - Atreca | 56 M USD |
| 2015-06-23 | Gladius Pharmaceuticals | GlaxoSmithKline investment in Series A - Gladius Pharmaceuticals | 4.1 M CAD |
Newest Events participated
Participated in OrphanDrug Congress USA 2017
on 2017-04-19 as sponsor
Participated in China Dental Show & CSA Annual Meeting
on 2015-09-24 as exhibitor
Participated in EAP Congress and MasterCourse 2015
on 2015-09-17 as sponsor
Participated in North Carolina Science Festival
on 2015-04-10 as sponsor
Participated in Big Bang Fair 2015
on 2015-03-11 as sponsor
Key Employee Changes
Official Site Inspections
http://www.gsk.com Semrush global rank: 78.15 K Semrush visits lastest month: 1.37 M
- Host name: 221.83.117.34.bc.googleusercontent.com
- IP address: 34.117.83.221
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "GlaxoSmithKline"
Home | GSK
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United …See details»
Company | GSK
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United …See details»
Company | GSK Canada
Nov 18, 2014 Trademarks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. GlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R …See details»
Board of directors and leadership team - GSK
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG > Modern Slavery Act statement …See details»
GSK plc - Wikipedia
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and …See details»
Company | GSK US
Getting ahead of disease is one of the greatest, most inspiring challenges there is on the planet. By pursuing this purpose together, we have the scale and expertise to positively impact the health of 2.5 billion people by the end of the decade. In …See details»
Canada leadership team - GSK
Trademarks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. GlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1 > GSK Modern Slavery …See details»
Purpose, strategy and culture | GSK US
GSK is a company where outstanding people can thrive. We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science …See details»
Governance - GSK
Ahead Together oversight. Our Board focuses on priorities agreed for the year to support delivery of GSK’s corporate strategy encapsulated in our Ahead Together ambitions. Our Board and management agendas are completely aligned with …See details»
GSK - Leadership Team - The Org
The Leadership Team at GSK is responsible for setting the strategic direction and operational oversight of the company. Comprising senior executives from various functions, including strategy, commercial, and scientific domains, this team …See details»
Purpose, strategy and culture | GSK Canada
GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company. We prioritize innovation in vaccines …See details»
Home | GSK US
The 2024 GSK IMPACT Award winners are transforming lives through innovative programs that address hunger, mentorship, homelessness, and education, making communities healthier …See details»
Purpose, strategy and culture - GSK
Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, …See details»
Diversity, equity and inclusion | GSK US
GSK has been focused on diversity, equity and inclusion for more than 30 years. That's because we have long seen the solution and innovations that come from a collective of unique minds. …See details»
Corporate Governance - GSK
Prior to her appointment as GSK’s CEO, Emma was the CEO of GSK Consumer Healthcare, a Joint Venture between GSK and Novartis, from its creation in March 2015. Emma joined GSK …See details»
GSK Canada unveils new head office, embracing a hybrid working …
Jun 15, 2022 The opening of GSK Canada’s new head office coincidences with the unveiling on June 9, 2022, of the company’s revamped branding, reflecting its new purpose—uniting …See details»
GSK Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 GSK has 5 employees across 149 locations and £30.33 b in annual revenue in FY 2023. See insights on GSK including office locations, competitors, revenue, financials, …See details»
GSK at a glance | GSK
GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG > Modern Slavery Act statement 2023 (PDF - …See details»
GSK named one of Canada’s Top 100 Employers in the year of the …
Mississauga, Ontario - GSK has been named as one of Canada’s Top 100 Employers for 2021. This award, the second consecutive time that GSK has been celebrated in this way, …See details»
Linerixibat shows positive Phase III results in cholestatic ... - GSK
Nov 19, 2024 GSK plc (LSE/NYSE: GSK) today announced positive headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational …See details»